1 / 9

Bezafibrate Infarction Prevention Trial (BIP)

Bezafibrate Infarction Prevention Trial (BIP). Results Presented at the European Society of Cardiology Meeting Vienna, Austria 1998. BIP - Study Design. 3,122 men and women between 45 and 75 with documented CAD. 400 mg bezafibrate vs. placebo. Lipid parameters: LDL < 180 mg/dL

kaiyo
Télécharger la présentation

Bezafibrate Infarction Prevention Trial (BIP)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Bezafibrate Infarction Prevention Trial (BIP) Results Presented at the European Society of Cardiology Meeting Vienna, Austria 1998

  2. BIP - Study Design • 3,122 men and women between 45 and 75 with documented CAD. • 400 mg bezafibrate vs. placebo. • Lipid parameters: • LDL < 180 mg/dL • TG < 300 mg/dL • HDL < 45 mg/dL • TC 180-250 mg/dL • Primary endpoint: • CHD death and non-fatal MI

  3. BIP - Baseline Characteristics Characteristic Age, yr 60 Women 9% Current Smokers 11% Diabetics 10% Hypertension 32% Prior MI 78% ASA use 70% Beta Blocker use 38% ACEI use 12%

  4. BIP - Baseline Lipids • TC 212 mg/dL • LDL 148 mg/dL • HDL 35 mg/dL • TG 149 mg/dL

  5. BIP - Change in Lipids/Fibrinogen

  6. BIP - Primary Endpoint 9% relative risk reduction p=0.27

  7. BIP - Conclusion • The primary endpoint was not significantly effected by bezafibrate therapy. • In a subset of patients with baseline TG > 200 mg/dL (n=459), there was a 40% reduction in the primary endpoint (p=0.03)

  8. Why Was VA-HIT Positive and BIP Negative? • BIP • bezafibrate 400 mg/day • VA-HIT • gemfibrozil 1200 mg/day • The VA-HIT population was: • Older • More obese • More hypertensive • More diabetics • More smokers • Had lower baseline LDL/HDL

  9. VA-HIT vs. BIPBaseline Characteristics Characteristic BIP (n=3,122) VA-HIT (n-2,531) LDL, mg/dL 148 111 TG, mg/dL 149 161 HDL, mg/dL 35 32 TC, mg/dL 212 175 Mean age, y 60 64 (70% > 60) Hypertension, % 32 57 Smokers, % 11 21 Diabetes, % 10 25 BMI 27 29

More Related